Khemlal Nirmalkar

Research Scientist

Arizona State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Sulfonation is one of the two main phase II detoxification pathways in eukaryotes which transforms nonpolar compounds into hydrophilic metabolites. Sulfotransferases catalyze these reactions by transferring a sulfo group from a donor to an acceptor molecule. Human cytosolic sulfotransferases use only 3′-phosphoadenosine 5′-phosphosulfate (PAPS) as a donor to sulfonate a variety of chemicals. Less understood are microbial aryl-sulfate sulfotransferases (ASSTs), which catalyze sulfo transfer reactions, without utilizing PAPS as a donor. Currently, the identity of physiological sulfo donor substrates remains unknown and sulfo acceptor substrates are underexplored. With this study, we aim to understand the potential contribution of a gut microbial enzyme to sulfonation chemistry by uncovering its substrate preferences. Here, we show that a sulfotransferase (Bacteroides vulgatus ASST) from the prevalent gut microbe B. vulgatus (now Phocaeicola vulgatus) is a versatile catalyst that utilizes a wide range of phenolic molecules as substrates that are commonly encountered by the host. With this action, it modulates concentrations of donor phenolic sulfates such as acetaminophen sulfate, dopamine sulfate, p-cresol sulfate, and related compounds in vitro and displays broad acceptor flexibility by sulfonating diverse phenolic compounds, including p-coumaric acid, p-cresol, 4-ethylphenol, tyramine, among others. These findings suggest that gut microbial enzymes like ASSTs may contribute to host detoxification of phenolics, a role previously attributed solely to human sulfotransferases. However, further in vivo studies are necessary to understand the potential contributions of ASSTs to host detoxification processes.

Year:

2026

Year:

2025

Para-cresol (p-cresol), and its primary human metabolite p-cresol sulfate (pCS), are among the most studied gut-derived metabolites relevant to autism spectrum disorder (ASD). P-cresol is produced by bacterial modification of phenylalanine or tyrosine and is one of many potentially deleterious metabolites produced by the gut microbiota. Seventeen studies have observed p-cresol and/or p-cresol sulfate as being higher in the urine of children with autism spectrum disorder (ASD) vs. controls. P-cresol has harmful effects on the body, including within the gut, brain, kidneys, liver, immune system, and mitochondria. Some of these effects may contribute to autism and comorbid symptoms. In the gut, p-cresol acts as an antibiotic, altering the gut microbiome to favor the bacteria that produce it. In the mitochondria, p-cresol disrupts ATP production and increases oxidative stress, which is also common in autism. In the brain, p-cresol impairs neuronal development. P-cresol inactivates dopamine beta-hydroxylase, which converts dopamine to noradrenaline. P-cresol sulfate impairs kidney function and is linked to chronic kidney disease (CKD), which is more common in ASD adults. P-cresol also interferes with immune function. Three animal studies have demonstrated that p-cresol causes autism-related symptoms in mice, and that mice can be recovered by the administration of fecal microbiota transplant from healthy mice. Similarly, it was found that microbiota transplant therapy treatment in children with ASD significantly reduced p-cresol sulfate levels to normal and led to significant improvements in gastrointestinal (GI) and ASD symptoms. In summary, p-cresol and pCS likely contribute to ASD core symptoms in a substantial subset of children with ASD.

Year:

2025

Year:

2025

Background Bile acids (BA), synthesized from cholesterol in the liver, are crucial for lipid digestion and absorption. In the gastrointestinal tract, primary bile acids are converted by host microbiota into various secondary and conjugated bile acids. Disordered microbiomes can alter the composition and concentration of the bile acid pool, impacting human health. Normally, blood levels of bile acids are low, but they can increase due to disorders such as liver disease. Consequently, identifying and quantifying these compounds has become a significant research focus. We present a highly selective targeted MS2 and MS3 approach for the quantitation of bile acids and their conjugates in serum using the Thermo Scientific™ Stellar™ mass spectrometer. Methods Unlabeled and stable-isotope-labeled bile acid standards were purchased from Cambridge Isotope Laboratories. These standards were used to prepare dilution series solutions in 50% methanol and generate calibration curves. Bile acids were extracted from the serum of adults with and without autism spectrum disorder (ASD) using 80% methanol, separated on a reverse-phase C18 column, and analyzed using the Thermo Scientific™ Stellar™ mass spectrometer. A scheduled method combining targeted-MS2 and targeted-MS3 scan modes with two activation types, CID and HCD, was employed to quantify these molecules. Data was processed using TraceFinder™ 5.2 software. Results The BA standards were utilized to generate calibration curves for absolute quantitation, facilitating reliable ion trap quantitation over a wide dynamic range of 5 to 6 orders of magnitude for the targeted BA. The MSn-based quantitation of the mass analyzer provided the selectivity needed to detect and accurately quantify co-eluting isomers and isobars, while also improving discrimination between analyte signals and matrix interferences. The new Stellar mass spectrometer enhances quantitative methods by combining different activation types and integrating targeted MS2 and MS3 acquisition modes in a single run. Bile acid standard curves (0.1 to 1000 nM) demonstrated a dynamic range over 5 orders of magnitude and excellent sensitivity in the femtomole range. Enhanced selectivity was achieved with MS3 acquisition, allowing accurate quantitation of co-eluting isomers that MS2 could not separate. This platform also provides valuable structural insights, potentially eliminating the need for extended chromatographic separation. The developed method was successfully employed to quantify metabolites in fecal samples. Conclusion High specificity and sensitivity with combined MS2 and MS3 levels for the quantitation of bile acids in blood

Year:

2025

Background Microbiota transplant therapy (MTT) is a promising avenue for the substantial improvement of gastrointestinal and behavioral symptoms in children with autism spectrum disorder (ASD). Previous work has demonstrated that microbiome and metabolite profiles of children with ASD become more similar to those of their typically developing (TD) peers following MTT. Methods To enhance a systems-level understanding of MTT in ASD children that extends beyond previously reported findings, we present a multi-omics analysis of an ASD cohort spanning 10 weeks and 2 years of follow-up after completion of MTT. We applied cutting-edge multi-omics approaches, including metagenomics, fecal and plasma metabolomics, and advanced statistical methods, including multimodal machine learning, differential network analysis, and causal mediation analysis, to extensively characterize molecular and biochemical responses before and after MTT, to identify key taxonomic, functional, and metabolite signatures associated with MTT treatment and ASD symptoms. Results Using a combination of cross-sectional and longitudinal statistical analyses and integrative machine learning techniques, we identified key meta-omic features associated with MTT. Integrated multi-omics analysis revealed that children with ASD transition to distinct biological states following MTT, clearly separated from their pre-treatment states and from TD children, as demonstrated by robust group separation and strong classification performance. Several biological signals associated with the modulation of the gut microbiome after MTT were identified, including an increase of butyrate producers such as Faecalibacterium prausnitzii and Butyricimonas faecalis ; decreased fecal sulfated primary bile acid, chenodeoxycholic acid sulfate; decreased secondary bile acid, glycolithocholate sulfate; and increased sarcosine and iminodiacetate in plasma after 10 weeks of MTT compared to baseline. Differential network analysis revealed hub species, including Prevotella copri , Ruminococcus callidus , and GGB9633 SGB15091 , as differentially connected 2 years after completion of MTT compared to baseline. Mediation analysis uncovered several key players as mediators of symptoms, including Alistipes ihumii , Ruminococceae , amino acid biosynthesis, bile acids, long-chain fatty acids, and cysteine-glutathione disulfide, among others. Conclusions This study provides one of the first comprehensive analyses of multi-omic features underlying host–microbiome interactions associated with MTT in children with ASD. It offers further evidence that fusing data across diverse molecular modalities at pre- and post- treatment time points can illuminate the potential of MTT in neurodevelopmental disorders. These findings could advance microbiome-based immunomodulatory therapies and multi-omics strategies to restore gut microbiota in children with ASD, while aiding in the discovery of novel biomarkers predictive of treatment response.

Year:

2025

Sulfonation is one of the two main phase II detoxification pathways in eukaryotes that transforms non-polar compounds into hydrophilic metabolites. Sulfotransferases catalyze these reactions by transferring a sulfo group from a donor to an acceptor molecule. Human cytosolic sulfotransferases use only 3’-phosphoadenosine 5’-phosphosulfate (PAPS) as a donor to sulfonate a variety of chemicals. Less understood are microbial aryl-sulfate sulfotransferases (ASSTs), which catalyze sulfo transfer reactions, without utilizing PAPS as a donor. Currently, the identity of physiological sulfo donor substrates remains unknown and sulfo acceptor substrates are underexplored. With this study, we aim to understand the potential contribution of a gut microbial enzyme to sulfonation chemistry by uncovering substrate preferences. Here, we show that a sulfotransferase (BvASST) from the prevalent gut microbe Bacteroides vulgatus (now Phocaeicola vulgatus) is a versatile catalyst that utilizes a wide range of phenolic molecules as substrates that are commonly encountered by the host. With this action, it has the ability to modulate concentrations of donor phenolic sulfates like acetaminophen sulfate, dopamine sulfate, p-coumaric acid sulfate, indoxyl sulfate, and p-cresol sulfate in vitro . Moreover, we report a large adaptability in the acceptor preferences with the evidence of sulfonation for many biologically relevant phenolic molecules including p-coumaric acid, p-cresol, dopamine, acetaminophen, tyramine, and 4-ethylphenol. These results suggest that such gut microbial enzymes may impact the detoxification of a variety of phenolic molecules in the host, which were previously thought to be solely detoxified via human sulfotransferases. However, further in vivo studies are necessary to understand potential contributions of ASSTs in host detoxification processes.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (12)

Michael Sadowsky

University of Minnesota

UNITED STATES
View details

Chad R. Borges

Arizona State University

UNITED STATES
View details

Sarkis Mazmanian

Professor

California Institute of Technology

UNITED STATES
View details

Chen Liao

Assistant Professor

Dartmouth College

UNITED STATES
View details

Himel Mallick

Principal Investigator (Tenure-track Faculty)

Cornell University

UNITED STATES
View details

Alexander Khoruts

Faculty, Professor

University of Minnesota System

UNITED STATES
View details

Juergen Hahn

Professor

Rensselaer Polytechnic Institute

UNITED STATES
View details

James Adams

President's Professor

Arizona State University

UNITED STATES
View details

Rosa Krajmalnik-Brown

Arizona State University

UNITED STATES
View details

Joao Xavier

Full Member

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Dae-Wook Kang

Associate Professor

University of Toledo

UNITED STATES
View details

Dhara D. Shah

Assistant Professor

Arizona State University

UNITED STATES
View details